209 related articles for article (PubMed ID: 23496810)
1. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.
Al-Wathiqi F; Ahmad S; Khan Z
BMC Infect Dis; 2013 Mar; 13():126. PubMed ID: 23496810
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
3. Antifungal susceptibility profile and molecular identification of Cyp51C mutations in clinical and environmental isolates of Aspergillus flavus from Argentina.
Hermida-Alava K; Brito Devoto T; Sautua F; Gordó M; Scandiani M; Formento N; Luque A; Carmona M; Cuestas ML
Mycoses; 2021 Jan; 64(1):95-101. PubMed ID: 33001518
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Rudramurthy SM; Chakrabarti A; Geertsen E; Mouton JW; Meis JF
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):370-7. PubMed ID: 21937186
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of five antifungal agents against 199 clinical and environmental isolates of Aspergillus flavus, an opportunistic fungal pathogen.
Khodavaisy S; Badali H; Hashemi SJ; Aala F; Nazeri M; Nouripour-Sisakht S; Sorkherizi MS; Amirizad K; Aslani N; Rezaie S
J Mycol Med; 2016 Jun; 26(2):116-121. PubMed ID: 26948143
[TBL] [Abstract][Full Text] [Related]
7. Genetic Diversity and
Taghizadeh-Armaki M; Hedayati MT; Ansari S; Omran SM; Saber S; Rafati H; Zoll J; van der Lee HA; Melchers WJG; Verweij PE; Seyedmousavi S
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264849
[No Abstract] [Full Text] [Related]
8. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
9. In vitro antifungal susceptibility of clinical and environmental isolates of Aspergillus fumigatus and Aspergillus flavus in Brazil.
Bedin Denardi L; Hoch Dalla-Lana B; Pantella Kunz de Jesus F; Bittencourt Severo C; Morais Santurio J; Zanette RA; Hartz Alves S
Braz J Infect Dis; 2018; 22(1):30-36. PubMed ID: 29172033
[TBL] [Abstract][Full Text] [Related]
10. Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999.
Chandrasekar PH; Cutright JL; Manavathu EK
Diagn Microbiol Infect Dis; 2001 Dec; 41(4):211-4. PubMed ID: 11777662
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
13. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.
Araujo R; Pina-Vaz C; Rodrigues AG
Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101
[TBL] [Abstract][Full Text] [Related]
16. The Molecular Identification and Antifungal Susceptibility of Clinical Isolates of
Djenontin E; Costa JM; Mousavi B; Nguyen LDN; Guillot J; Delhaes L; Botterel F; Dannaoui E
Microorganisms; 2023 Sep; 11(10):. PubMed ID: 37894087
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.
Gomez-Lopez A; Garcia-Effron G; Mellado E; Monzon A; Rodriguez-Tudela JL; Cuenca-Estrella M
Antimicrob Agents Chemother; 2003 Oct; 47(10):3085-8. PubMed ID: 14506013
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus.
Krishnan-Natesan S; Chandrasekar PH; Alangaden GJ; Manavathu EK
Int J Antimicrob Agents; 2008 Dec; 32(6):519-24. PubMed ID: 18775650
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
Misra R; Malik A; Singhal S
Indian J Pathol Microbiol; 2011; 54(1):112-6. PubMed ID: 21393890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
